Compare BSRR & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSRR | ZURA |
|---|---|---|
| Founded | 1977 | 2022 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 479.7M | 435.0M |
| IPO Year | 2001 | N/A |
| Metric | BSRR | ZURA |
|---|---|---|
| Price | $33.33 | $6.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $38.50 | $11.78 |
| AVG Volume (30 Days) | 46.1K | ★ 477.4K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.14% | N/A |
| EPS Growth | ★ 10.28 | N/A |
| EPS | ★ 3.11 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.63 | N/A |
| P/E Ratio | $10.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.42 | $0.99 |
| 52 Week High | $38.60 | $7.25 |
| Indicator | BSRR | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 35.00 | 47.23 |
| Support Level | $32.65 | $5.62 |
| Resistance Level | $34.71 | $6.90 |
| Average True Range (ATR) | 1.33 | 0.52 |
| MACD | -0.37 | -0.09 |
| Stochastic Oscillator | 19.54 | 12.84 |
Sierra Bancorp is a California-based bank holding company, which offers a range of retail and commercial banking services. it offers a wide range of deposit products and services for individuals and businesses including checking accounts, savings accounts, money market demand accounts, time deposits, retirement accounts, and sweep accounts. The company's lending activities cover real estate, commercial (including small business), mortgage warehouse, agricultural and consumer loans, and also offers commercial construction loans and multifamily and agricultural credit facilities among other types of real estate loans.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.